PM

PM is a high-quality compounder firing on the operating line: FY2025 net revenues of $40.6B grew 7.3% and accelerated off a multi-year ramp ($31.4B in 2021 → $40.6B in 2025), while gross margin held at a commanding 67.1% and operating margin at 36.6%. Operating income rose 11.1% to $14.9B. The headline +60.8% jump in net income to $11.3B overstates underlying momentum — FY2024 was depressed by a $2.3B RBH equity-investment impairment and goodwill charges, so the cleaner read is the ~11% growth in operating income and gross profit. Even normalized, this is durable, pricing-power-driven growth, and the smoke-free portfolio (IQOS, Zyn) is the genuine engine that justifies a multiple well above legacy-tobacco peers. Operating cash flow of $12.2B and ~$10.6B of free cash flow (OCF less $1.57B capex) confirm the earnings are real.

The balance sheet looks alarming on screen — stockholders' equity is -$9.99B and liabilities/equity is a meaningless -7.73x — but this is structural, not distress: decades of buybacks and dividends have eroded book equity, while the business remains solidly investment-grade (Moody's A2 stable, S&P A- positive, Fitch A). That said, leverage is real: MD&A discloses $48.8B of total debt (up from $45.7B), against only $4.87B of cash, with Swedish Match term-loan tranches and Euro/USD FX exposure on a $50B gross-notional derivative book that management itself flags as a drag on 'the pace of anticipated deleveraging.' Dividends paid of $8.62B already consume ~81% of free cash flow, leaving little cushion and explaining the absence of buybacks — the payout is covered but not comfortably, and the deleveraging path constrains capital returns.